Xceleron has signed a master services agreement with Sanofi-Aventis to assess the human metabolism of novel compounds in early clinical development. Prof. Colin Garner, Xceleron’s chief executive officer, said, “Xceleron is delighted to be working with Sanofi-Aventis to optimize their radiolabelled clinical studies. Increasingly, leading pharmaceutical companies are adopting Xceleron’s new drug development strategies to maximize data on compounds in the exploratory clinical developme...